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ABSTRACT   
  
Cardiovascular diseases are leading cause of death in western and eastern countries of the world. 
Hyperlipidemia is one of the strong risk fractions for heart diseases. To evaluate hypolipidemic 
drugs efficacy, the study was conducted at National hospital, Lahore Pakistan from January 2016 
to August 2016. Ninty hyperlipidemic patients were selected from cardiology and medical wards 
of the hospital. They were divided in three groups, one at placebo therapy, another on Kalonji 
and third one on Vitamin B3. After one and half month, significant changes (p value ranging 
from <0.05 to <0.001) were observed in their LDL and HDL-cholesterol. Conclusion of the 
study was to recommend use of herbal medicine and vitamin B3 for prevention of any heart 
diseases with good patient compliance. 
  
 
INTRODUCTION 
Coronary artery disease (CAD)occurs when the inside (the lumen) of one or more coronary 
arteries narrows, limiting the flow of oxygen-rich blood to surrounding heart muscle tissue. 
Atherosclerosis is the process that causes the artery wall to get thick and stiff. It can lead to 
complete blockage of the artery, which can cause a heart attack
1
. The disease process begins 
when LDL  deposits cholesterol in the artery wall. The body has an immune response to protect 
itself and sends white blood cells called macrophages to engulf the invading cholesterol in the 
artery wall. When the macrophages are full of cholesterol, they are called foam cellsbecause of 
their appearance. As more foam cells collect in the artery wall, a fatty streak develops between 
the intima and the media. If the process is not stopped, the fatty streak becomes a plaque, which 
pushes the intima into the lumen, narrowing the blood flow
2-6
. With few exceptions, low HDL is 
an independent risk factor for CAD in case-control and prospective observational studies
7
. In 
contrast, high HDL levels are associated with longevity and are protective against the 
development of atherosclerotic disease
8
. In the Framingham Study, risk for CAD increases 
sharply as HDL levels fall progressively below 40 mg/dL
9-10
. In the Quebec Cardiovascular 
Study, for every 10% reduction in HDL, risk for CAD increased 13%.
2
 Many clinicians believe 
that low HDL is associated with increased CAD risk because it is a marker for 
hypertriglyceridemia and elevated remnant particle concentrations. The Prospective 
Cardiovascular Münster Study, however, demonstrated that the increased risk associated with 
low HDL is independent of serum triglyceride levels
11
. There is considerable controversy about 
whether one HDL subfraction is more antiatherogenic than others. At the present time, the 
preponderance of evidence favors increasing total HDL mass, rather than any one subfraction of 
this lipoprotein
12
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MATERIAL & METHOD 
 
 The study was conducted at National hospital, Lahore Pakistan from January 2016 to August 
2016. Ninty patients were selected for study. Consent was taken from all participants. Inclusion 
criteria was primary and secondary hyperlipidemic patients. Exclusion criteria was patients 
suffering from any kidney, liver and thyroid related disease. Name, age, gender, occupation, 
residential address, phone/contact number, previous medical history, disease in family history, 
drug history were recorded in specific Performa. Three groups I, II, and III were made (30 
patients in each group). Group-I was allocated for placebo, to take placebo capsule once daily, 
after breakfast for six weeks. Group-II was advised to take 2 tea spoons of kalonji after breakfast 
for the period of six weeks. Group-III was on Niacin 2 grams in divided doses, after breakfast, 
lunch and dinner for 6 weeks. Their base line LDL-cholesterol and HDL-cholesterol level was 
estimated at the start of research work. Their serum was taken at follow up visits, fortnightly for 
lipid profile. Data were expressed as the mean±SD and ‘t’ test was applied to determine 
statistical difference in results. A p-value > 0.05 was considered as non-significance and P-value 
< 0.001 was considered as highly significant change in the differences. Serum LDL-cholesterol 
was calculated by formula (LDL-Cholesterol=Total Cholesterol-(Triglycerides/5 +HDL-
Cholesterol). Serum HDL-cholesterol was determined by using kit Cat. # 3022899 by Eli Tech 
Diagnostic, France. 
 
RESULTS 
 
Numerical values and results of all parameters of participated patients  were analyzed 
biostatistically.  In placebo group, LDL-cholesterol decreased from 189.15±3.90 mg/dl to 
186.75±2.08 mg/dl, change in the parameter is 2.40 mg/dl.  This difference in pretreatment and 
post treatment value is non-significant, ie;  P-value > 0.05. HDL-cholesterol in placebo group 
increased from 36.11±2.11mg/dl to 37.17±1.51mg/dl. The difference in parameter was 
1.06mg/dl. Statistically this change in parameter was nonsignificant, ie; P-value > 0.05. In 
Nigella sativa group , out of 30 hyperlipidemic patients, 27 patients completed over all study 
period. LDL-cholesterol in this group decreased from 202.45±1.54mg/dl to 189.52±2.21mg/dl. 
The difference in pretreatment and postreatment mean values is 12.93 mg/dl. Statistically this 
change in two mean values is highly significant, with p-value < 0.001. HDL-cholesterol in this 
group increased from 38.81±3.90 42.19±3.32mg/dl. Change in two mean values was 3.38mg/dl. 
Statistically this change is significant, with probability value <0.01. In group III, 28 patients 
completed the research. LDL-cholesterol in this group decreased from 212.65±2.32 to 
185.61±3.43 mg/dl in six weeks treatment. Change in pre and post treatment mean values is 
27.04mg/dl. Statistically this change is highly significant, i.e., P-value < 0.001. HDL-cholesterol 
increased from 39.19±2.01 to 43.00±3.07 mg/dl in six weeks. Change in two parallel values is 
3.49mg/dl, which is significant with P-value <0.01.  
 
  
 
 
 
  
 
Table: 1-LDL, HDL’s  basic values (pre and after treatment) and their 
biostatistical significance 
No. Of 
patients 
Day-0 values Day-45 values Change in basic values Statistical 
significance 
Placebo (30 
pts) 
LDL-
c=189.15±3.90 
HDL-
c=36.11±2.11 
LDL=186.75±2.08 
HDL=37.17±1.51 
2.40 
1.06 
> 0.05 
> 0.05 
Kalonji (27 
pts) 
LDL-
c=202.45±1.54 
HDL-
c=38.81±3.90 
LDL=189.52±2.21 
HDL=42.19±3.32 
12.93 
3.38 
< 0.001 
< 0.01 
Vit B3 (28 
pts) 
LDL-
c=212.65±2.32 
HDL-
c=39.19±2.01 
LDL=185.61±3.43 
HDL=43.00±3.07 
27.04 
3.49 
< 0.001 
< 0.01 
KEY: HDL and LDL are measured in mg/dl, n stands for sample size, p-value >0.05 indicate 
non-significant, <0.01 indicate significant and <0.001 indicate highly significant change in basic 
values 
 DISCUSSION 
 There are new guidelines recommended by W.H.O for treatment of hypertension, 
hyperglycemia, hyperlipidemia. Guidelines also emphasize on new determinants of  prevention 
of dyslipidemia. In our results treatment with three weeks, Kalonji decreased LDL-cholesterol 
12.93 mg/dl by six weeks of treatment. HDL-cholesterol increased 3.38 mg/dl by taking this 
drug for six weeks. The change in both parameters were significant. In placebo group, LDL-C 
reduction was 2.40 mg/dl and increase in HDL-C was 1.06 mg/dl with P-value >0.05, which 
proves non-significant change in results. These results match with Akhondian  et al
13
 who did 
prove that Nigella sativa is very effective hypolipidemic drug. He tested the drug on 120 
hyperlipidemic and diabetic patients by using Nigella sativa for one month. Their results were 
highly significant when compared with placebo-controlled group. Our results also match with 
results of Gillani AH et al
14
 who proved LDL-Cholesterol reduction from 201.61±3.11 mg/dl to 
187.16±2.10 mg/dl in fourty hyperlipidemic patients. Their HDL-C increase was 3.98 mg/dl 
which also matches with our results. Results of our study are in contrast with results of research 
work conducted by AH BH and Blunden G
15
 .  They explained that  some active ingredients of 
Nigella sativa are hypolipidemic but their hypolipidemic effects are very narrow spectrum.  Their 
results showd only 2.11 mg/dl change in LDL-C and 0.92 mg/dl increase in HDL-C of 38 rats. 
Difference in results may be genetic variants of human and rats. Brown BG et al
16
 also described 
phenomenon of genetic variation in pharmacological effects of Nigella sativa. Burits M & Bucar 
F
17
 have also mentioned wide variety  effects of Nigella sativa with different genetic make 
ups.  Our results also match with results of research work of Dehkordi FR & Kamkhah AF
18
 and 
El-Dakhakhany M
19
. Same mechanism of action of drug Nigella sativa is described by El-Din K 
et al
20
. In our research Niacin  reduced LDL-Cholesterol from 212.65±1.19 mg/dl to 185.61±1.65 
mg/dl in six weeks. This reduction in LDL-C was 27.04 mg/dl, which is highly significant 
change, when analyzed statistically. These results match with resultsn of research work 
conducted by  Afilalo J et al
21
 who proved almost same change in LDL-C in 32 hyperlipidemic 
  
 
patients who were cases of secondary hyperlipidemia and used Niacin 2 grams daily for two 
months. Their LDL-C reduction was 25.55 mg/dl. Their HDL-C increase was 6.65 mg/dl in 2 
months. In our results HDL-C increase was 3.81 mg/dl in six weeks use of Niacin. Our results 
also match with results of research conducted by Whitney EJ et al
22
 who proved 27.77 mg/dl 
reduction in LDL-C in 19 hyperlipidemic patients. Ginsberg HN et al
23
 also support our results, 
as they proved 4.00 mg/dl increase in HDL-C when two grams of Niacin was used in 34 
hyperlipidemic patients for six weeks. Our results do not match with results of research 
conducted by Boden WE et al
24
 who proved that 2.5 grams Niacin decreased 10.99 mg/dl LDL-
Cholesterol. HDL-C increase was only 1.11 mg/dl. These differences may be considered due to 
lack of physical exercise and no restriction of use of lipids in their diet. Taylor AJ et al
25
 used 
Niacin 1.5 grams in 29 hyperlipidemic patients for 3 weeks. Patients reduced their LDL-C from 
189.88 ±1.11 mg/dl to 187.87±0.99 mg/dl. Difference in their results and our results is due to 
less sample size, lesser duration of exposure of patients to drug and small amount of drug given 
in their patients.  Mookr TT et al
26
 , Furhr GT
27
, Fekharj Y et al
28
 , Gamadr VF
29
, and Rusdan T 
et al
30
 explained that Niacin is drug of choice for treating and prevention of dyslipidemia. 
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